CNMD Stock - CONMED Corporation
Unlock GoAI Insights for CNMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.31B | $1.24B | $1.05B | $1.01B | $862.46M |
| Gross Profit | $733.03M | $676.25M | $571.25M | $568.04M | $460.30M |
| Gross Margin | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% |
| Operating Income | $200.33M | $120.60M | $70.05M | $109.72M | $46.01M |
| Net Income | $132.42M | $64.46M | $-80,582,000 | $62.54M | $9.52M |
| Net Margin | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% |
| EPS | $4.29 | $2.10 | $-2.68 | $2.14 | $0.33 |
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 12th 2025 | Needham | Downgrade | Hold | - |
| April 28th 2025 | Stifel | Downgrade | Hold | $55 |
| February 6th 2025 | JP Morgan | Downgrade | Neutral | $70← $85 |
| February 1st 2024 | Needham | Reiterated | Buy | $129← $119 |
| May 22nd 2023 | CL King | Initiation | Buy | $140 |
| March 27th 2023 | KeyBanc Capital Markets | Upgrade | Overweight | $124 |
| March 21st 2023 | Wells Fargo | Initiation | Equal Weight | $96 |
| October 12th 2022 | Jefferies | Initiation | Hold | $85 |
Earnings History & Surprises
CNMDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $1.32 | — | — | — |
Q4 2025 | Nov 5, 2025 | $1.05 | $1.08 | +2.9% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $1.13 | $1.15 | +1.8% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $0.81 | $0.95 | +17.3% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $1.20 | $1.34 | +11.7% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.99 | $1.05 | +6.1% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.91 | $0.98 | +7.7% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.74 | $0.79 | +6.8% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $1.11 | $1.06 | -4.5% | ✗ MISS |
Q4 2023 | Oct 25, 2023 | $0.83 | $0.90 | +8.4% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.79 | $0.83 | +5.1% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.60 | $0.66 | +10.0% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $0.93 | $0.42 | -54.8% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $0.75 | $0.77 | +2.7% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $0.76 | $0.76 | 0.0% | = MET |
Q2 2022 | May 4, 2022 | $0.62 | $0.70 | +12.9% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | $1.03 | $1.07 | +3.9% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.77 | $0.80 | +3.9% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.62 | $0.71 | +14.5% | ✓ BEAT |
Latest News
B of A Securities Maintains Neutral on Conmed, Lowers Price Target to $52
➖ NeutralCONMED shares are trading lower after the company announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy.
📉 NegativeConmed Intends To Exit Its Gastroenterology Product Lines As Part Of Its Broader Portfolio Optimization Strategy
➖ NeutralJP Morgan Maintains Neutral on Conmed, Lowers Price Target to $52
➖ NeutralPiper Sandler Maintains Overweight on Conmed, Lowers Price Target to $55
➖ NeutralWells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $47
📉 NegativeConmed Narrows FY2025 Adj EPS Guidance from $4.40-$4.55 to $4.48-$4.53 vs $4.47 Est; Narrows FY2025 Sales Guidance from $1.356B-$1.378B to $1.365B-$1.372B vs $1.368B Est
📈 PositiveConmed Q3 Adj. EPS $1.08 Beats $1.05 Estimate, Sales $337.900M Beat $334.760M Estimate
📈 PositiveFrequently Asked Questions about CNMD
What is CNMD's current stock price?
What is the analyst price target for CNMD?
What sector is CONMED Corporation in?
What is CNMD's market cap?
Does CNMD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CNMD for comparison